Publications by Fredrik Hellem Schjesvold

20 publications found

Publications 2019

1. Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC, ICARIA-MM study group (2019)
   Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
   Lancet (in press)
   DOI 10.1016/S0140-6736(19)32556-5, PubMed 31735560
2. Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H et al. (2019)
   International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
   Lancet Oncol, 20 (6), e302-e312
   DOI 10.1016/S1470-2045(19)30309-2, PubMed 31162104
3. Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P et al. (2019)
   Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
   Lancet Haematol, 6 (9), e459-e469
   DOI 10.1016/S2352-3026(19)30110-3, PubMed 31327687
4. Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M et al. (2019)
   Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
   Lancet Oncol, 20 (6), 781-794
   DOI 10.1016/S1470-2045(19)30152-4, PubMed 31097405
5. Usmani SZ, Schjesvold F, Oriol A, Karlin L, Cavo M, Rifkin RM, Yimer HA, LeBlanc R, Takezako N, McCroskey RD, Lim ABM, Suzuki K, Kosugi H, Grigoriadis G, Avivi I, Facon T, Jagannath S, Lonial S, Ghori RU, Farooqui MZH, Marinello P, San-Miguel J, KEYNOTE-185 Investigators (2019)
   Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
   Lancet Haematol, 6 (9), e448-e458
   DOI 10.1016/S2352-3026(19)30109-7, PubMed 31327689

Publications 2018

1. Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R et al. (2018)
   Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
   Lancet, 393 (10168), 253-264
   DOI 10.1016/S0140-6736(18)33003-4, PubMed 30545780
2. Tangen JM, Tjønnfjord GE, Gulbrandsen N, Gedde-Dahl T, Stormorken E, Anderson K, Vo CD, Schjesvold FH, For Oslo Myeloma Center (2018)
   Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: a retrospective, population based analysis
   BMC Cancer, 18 (1), 801
   DOI 10.1186/s12885-018-4722-x, PubMed 30089450
3. Thimiri Govinda Raj DB, Cremaschi A, Skånland SS, Gade A, Schjesvold FH, Tjønnfjord GE, Munthe LA, Tasken K (2018)
   In-Vitro Drug Sensitivity Screening in Chronic Lymphocytic Leukemia (CLL) Primary Patient Samples Identifies Drug Candidates for Precision Cancer Therapy
   Blood, 132, 4676
   DOI 10.1182/blood-2018-99-110357, PublikaID 304
4. Thimiri Govinda Raj DB, Giliberto M, Cremaschi A, Skånland SS, Gade A, Tjønnfjord GE, Schjesvold FH, Munthe LA, Tasken K (2018)
   Drug Sensitivity Screening on Multiple Myeloma for Precision Cancer Therapy
   Blood, 132, 4677
   DOI 10.1182/blood-2018-99-110669, PublikaID 303

Publications 2017

1. Schjesvold FH (2017)
   Immunologiske mekanismer for drap av kreftceller
   Tidsskr Nor Laegeforen, 137 (1), 58
   DOI 10.4045/tidsskr.16.0963, PubMed 28073239
2. Wang D, Fløisand Y, Myklebust CV, Bürgler S, Parente-Ribes A, Hofgaard PO, Bogen B, Taskén K, Tjønnfjord GE, Schjesvold F, Dalgaard J, Tveita A, Munthe LA (2017)
   Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice
   Leukemia, 31 (10), 2114-2121
   DOI 10.1038/leu.2017.69, PubMed 28232741

Publications 2016

1. Torfoss D, Fladhagen T, Holte H, Brinch L, Schjesvold FH, Fløisand Y, Nyquist E, Dalgaard J, Meyer P, Lehmann AK, Hammerstrøm J, Skjelbakken T, Høiby EA, Sandvik L, Kvaløy S (2016)
   Benzylpenicillin plus an aminoglycoside versus meropenem in neutropenic lymphoma and leukaemia patients with a suspected bacterial infection: a randomized, controlled trial
   Clin Microbiol Infect, 23 (3), 179-187
   DOI 10.1016/j.cmi.2016.10.019, PubMed 27793737

Publications 2015

1. Tveita AA, Schjesvold F, Haabeth OA, Fauskanger M, Bogen B (2015)
   Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens
   Cancer Res, 75 (16), 3268-78
   DOI 10.1158/0008-5472.CAN-14-3640, PubMed 26038231

Publications 2014

1. Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, Omholt H, Munthe LA, Dembic Z, Corthay A, Bogen B (2014)
   How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?
   Front Immunol, 5, 174
   DOI 10.3389/fimmu.2014.00174, PubMed 24782871
2. Tveita AA, Schjesvold FH, Sundnes O, Haabeth OA, Haraldsen G, Bogen B (2014)
   Indirect CD4+ T-cell-mediated elimination of MHC II(NEG) tumor cells is spatially restricted and fails to prevent escape of antigen-negative cells
   Eur J Immunol, 44 (9), 2625-37
   DOI 10.1002/eji.201444659, PubMed 24846412

Publications 2013

1. Schjesvold F, Wiencke K, Tjønnfjord GE (2013)
   [Investigation of anemia]
   Tidsskr Nor Laegeforen, 133 (6), 610
   DOI 10.4045/tidsskr.13.0256, PubMed 23552139
2. Schjesvold FH (2013)
   [Investigation of amyloidosis]
   Tidsskr Nor Laegeforen, 133 (3), 266
   DOI 10.4045/tidsskr.13.0044, PubMed 23381155

Publications 2012

1. Tazmini K, Bakken HN, Schjesvold FH (2012)
   A woman in her seventies with reduced general condition, dyspnoea and generalised pain
   Tidsskr Nor Laegeforen, 132 (17), 1969-72
   DOI 10.4045/tidsskr.11.0608, PubMed 23007363

Publications 2009

1. Schjesvold FH (2009)
   [Erythrocytosis as a problem]
   Tidsskr Nor Laegeforen, 129 (22), 2387; author reply 2387
   DOI 10.4045/tidsskr.09.1196, PubMed 19935946

Publications 2008

1. Schjesvold FH, Sjo M, Tangen JM, Hammerstrøm J, Brinch L (2008)
   [High-dose treatment of systemic AL-amyloidosis with autologous stem cell support]
   Tidsskr Nor Laegeforen, 128 (12), 1392-6
   PubMed 18552900